|
US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
|
NL296693A
(forum.php)
*
|
1962-08-16 |
|
|
|
|
DK111894A
(forum.php)
|
1962-11-15 |
|
|
|
|
FR95908E
(fr)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
|
|
DE1231704B
(de)
|
1963-12-19 |
1967-01-05 |
Josef Klosa Dipl Chem Dr Rer N |
Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
|
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
|
DE2902172C2
(de)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
|
|
WO1983003755A1
(en)
*
|
1982-04-23 |
1983-11-10 |
Caola Kozmetikai És Háztartäsvegyipari Vállalat |
Novel cosmetic compositions containing prenylamine and a process for their preparation
|
|
NZ215753A
(en)
*
|
1985-04-16 |
1989-10-27 |
Hoffmann La Roche |
Phenethanolamine derivatives and pharmaceutical compositions
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
AR032403A1
(es)
*
|
2001-01-26 |
2003-11-05 |
Schering Corp |
Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
|
|
AU2002241956A1
(en)
*
|
2001-01-26 |
2002-08-06 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
CA2434488A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
AU2002243557B2
(en)
*
|
2001-01-26 |
2006-01-05 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
|
ATE362757T1
(de)
*
|
2001-01-26 |
2007-06-15 |
Schering Corp |
Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
PL208110B1
(pl)
*
|
2001-01-26 |
2011-03-31 |
Schering Corp |
Kompozycja farmaceutyczna
|
|
DE60216275T2
(de)
*
|
2001-05-25 |
2007-06-21 |
Schering Corp. |
Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US7132415B2
(en)
*
|
2001-09-21 |
2006-11-07 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
PT1427409E
(pt)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
OA12905A
(en)
|
2002-08-19 |
2006-10-13 |
Pfizer Prod Inc |
Combination therapy for hyperproliferative diseases.
|
|
MXPA05004810A
(es)
*
|
2002-11-06 |
2005-07-22 |
Schering Corp |
Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion.
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
EP1606287B1
(en)
*
|
2003-03-07 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
DE602004016123D1
(de)
*
|
2003-03-07 |
2008-10-09 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
|
DE602004018617D1
(de)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
|
EP1680189A2
(en)
*
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
|
RU2007106714A
(ru)
*
|
2004-07-26 |
2008-09-10 |
Байер Шеринг Фарма Аг (De) |
Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
ATE551059T1
(de)
*
|
2005-10-26 |
2012-04-15 |
Asahi Kasei Pharma Corp |
Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
|
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8883844B2
(en)
|
2010-09-24 |
2014-11-11 |
Nitrogenix Inc. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
SG11201507496UA
(en)
|
2013-04-17 |
2015-11-27 |
Pfizer |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
CN105764916B
(zh)
|
2013-06-05 |
2021-05-18 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
SI3911648T1
(sl)
|
2019-01-18 |
2025-02-28 |
Astrazeneca Ab |
6'-[[(1S,3S)-3-[[5-(difluorometoksi)-2-pyrimidinil]amino]ciklopentil]amino][1(2H),3'-bipiridin]-2-on kot zaviralec PCSK9 in postopki njegove uporabe
|